IPO
Artiva Pursues IPO to Fund NK Cell Therapy After Losing Merck Partnership
Artiva, Merck, IPO, NK Cell Therapy, Biotech, Partnership, Funding
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings
Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season
Rapport, IPO, J&J, neuroscience, biotech, summer plans, Third Rock.
Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering
Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health
“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”
Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist
Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline
Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307
Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO
Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024